Immune / inflammation

LL-37

Cathelicidin / innate immunity and microbial membranes · Peptide
Also known as ll-37 Ll 37

Evidence at a glance

Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.

Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.

Open in the interactive library →Compare with other compounds →

Records (2)

Human clinical / research

LL-37 topical venous leg ulcer phase IIb trial

Administration reported for this specific study or labeled indication.

Context: Adults with hard-to-heal venous leg ulcers

Human study regimen: Amount: 0.5 or 1.6 mg/mL, applied at 25 µL/cm²; Route: Topical wound bed; Frequency: Every third day ±1 day, at most twice weekly; Species: Human; Population: Adults with hard-to-heal venous leg ulcers

Limitations: The concentrations delivered 12.5 or 40 µg/cm² with standard care. Overall healing superiority was not demonstrated.

Route: Topical wound bed

LL-37 topical venous leg ulcer phase IIb trial ↗

Open this exact record in the library →Suggest a correction

Unresolved / evidence gap

Systemic treatment gap

Innate immune and wound biology is described; systemic self-injection protocol is not validated here.

Context: Imported field-guide summary; primary citation incomplete.

Limitations: No primary study or systemic PK anchor supplied.

Route: Not documented

Peptide Protocol Field Guide · version 7

Open this exact record in the library →Suggest a correction

CONTINUE THE RESEARCH

Follow the pathway.

These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.

Browse this pathway in the library →

Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.